There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Constellation Pharmaceuticals (CNST), Aurinia Pharmaceuticals (AUPH) and Masimo (MASI) with bullish sentiments.
Constellation Pharmaceuticals (CNST)
In a report issued on December 7, Michael Ulz from Robert W. Baird reiterated a Buy rating on Constellation Pharmaceuticals, with a price target of $45.00. The company’s shares closed last Thursday at $26.71.
According to TipRanks.com, Ulz is a 3-star analyst with an average return of 7.8% and a 48.3% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Constellation Pharmaceuticals with a $47.80 average price target, representing a 71.0% upside. In a report issued on December 7, Brookline Capital Markets also initiated coverage with a Buy rating on the stock with a $33.00 price target.
See today’s analyst top recommended stocks >>
Aurinia Pharmaceuticals (AUPH)
In a report issued on December 16, Ed Arce from H.C. Wainwright maintained a Buy rating on Aurinia Pharmaceuticals, with a price target of $28.00. The company’s shares closed last Thursday at $14.58.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 16.9% and a 43.3% success rate. Arce covers the Healthcare sector, focusing on stocks such as Paratek Pharmaceuticals, Mirum Pharmaceuticals, and Arcturus Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aurinia Pharmaceuticals with a $29.14 average price target, a 94.3% upside from current levels. In a report issued on December 4, Cowen & Co. also maintained a Buy rating on the stock with a $30.00 price target.
Masimo (MASI)
Robert W. Baird analyst Michael Polark maintained a Buy rating on Masimo on January 13. The company’s shares closed last Thursday at $246.11.
According to TipRanks.com, Polark is a 3-star analyst with an average return of 12.7% and a 65.2% success rate. Polark covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Inspire Medical Systems, and Irhythm Technologies.
Currently, the analyst consensus on Masimo is a Moderate Buy with an average price target of $301.25, which is a 19.9% upside from current levels. In a report issued on January 20, Raymond James also initiated coverage with a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MASI:
